The COVID-19 Vaccine Breakthroughs and the Work Ahead
Scroll to read more or
PhRMA COVID-19 Treatment Progress
America’s biopharmaceutical companies turned a once in a generation challenge into reality by delivering safe and effective COVID-19 vaccines and treatments to patients in record time. COVID-19 vaccines have leaned on new platform technologies and scientific advancements, which have transformed how we fight infectious disease. Innovative treatment approaches have further reduced hospitalizing for severe infection. But our work isn’t done. As variants emerge, the biopharmaceutical industry is working to learn more, be prepared and develop additional solutions to protect us against COVID-19 and future pandemics.
The biopharmaceutical industry has provided financial support and in-kind donations to organizations, patients and first responders, and continues to collaborate with U.S. and global health authorities to combat this global public health emergency.
The biopharmaceutical industry has provided financial support and in-kind donations to organizations, patients and first responders, and continues to collaborate with U.S. and global health authorities to combat this global public health emergency.
Our Commitment
Our Commitment to Beat Coronavirus
We came together to achieve one shared goal: to beat COVID-19. The groundbreaking COVID-19 vaccines and therapies bring us closer to accomplishing this goal, but we are not done yet. The decades-long investments we have made in new technology, research and treatments have prepared us to act swiftly and allowed us to be in the position to:
Continue researching and developing potential treatments and vaccines, and conducting clinical trials for additional patient populations.
Dedicate investments in new technologies to stay ahead of emerging variants with safe and effective vaccines.
Share the learnings from clinical trials in real time with governments and other companies to advance the development of additional therapies.
Expand our customized manufacturing capabilities via partnerships with fellow biopharmaceutical companies and share available capacity to increase vaccine manufacturing.
Collaborate with government agencies, hospitals, doctors and others to donate supplies and medicines to help those affected by COVID-19 around the world.
Partner with governments and insurers to ensure that treatments and vaccines are available and affordable for all patients.
We’ve delivered on the promise of medicine, but our work isn’t done. And while we work hard to beat COVID-19, we’re already thinking about the breakthroughs on the horizon.
Learn more about the COVID-19 work our industry has done.
Updates/Alerts
Related
Related Resources
Our Work Is Not Done
The toughest of times brought out the best in us. America's innovative research ecosystem delivered multiple COVID-19 vaccines. But our work is not done — from working to combat variants, find new treatments and make as many vaccines as the world needs. While you do your part to stay safe, we'll continue to do ours. Together, we’ll get back to normal.
Biopharmaceutical Companies Are Supporting India During the Coronavirus Crisis
From providing financial support and in-kind donations to organizations, to building capacity with Indian manufacturers and entering into licensing agreements, America’s biopharmaceutical companies stand with everyone affected by the terrible COVID-19 surge in India and patients around the world.
COVID-19 Vaccine Research and Development
As the COVID-19 pandemic continues to impact patients worldwide, America’s biopharmaceutical research companies are working around the clock with stakeholders across the research and development (R&D) ecosystem to advance vaccine candidates that will help prevent infection and stop the spread of the virus.
2020 Industry Profile Toolkit: The Biopharmaceutical Industry's Unique Role in Responding to COVID-19
As the outbreak of COVID-19 – a disease caused by a novel strain of coronavirus – evolves in the United States and around the globe, the biopharmaceutical industry is working around the clock to find solutions.
Innovation in COVID-19
American biopharmaceutical companies have been working around the clock for more than a year with the primary objective of ending the pandemic. These efforts, made possible through unprecedented collaborations, have resulted in multiple vaccines and treatments receiving emergency use authorization for use in the United States including one treatment receiving approval for the treatment of severe COVID-19 infection.
Working Together To Fight COVID-19: Vaccine Manufacturing Collaborations
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 vaccine manufacturing. Even prior to knowing the efficacy of particular vaccine candidates, companies have proactively been increasing their own manufacturing capabilities as well as partnering with other manufacturers who are sharing available capacity to support production. These partnerships have been key to manufacturing ramp-up following vaccine authorization.
How Industry Collaboration and Partnerships are Supporting COVID-19 Vaccine Manufacturing
Across the industry, biopharmaceutical companies are working around the clock to meet the demands of COVID-19 manufacturing. To overcome hurdles in global vaccination efforts, biopharmaceutical companies have established partnerships to help support increased manufacturing output and speed up the ability to fight COVID-19 as distribution capacity is expanded around the globe.
Industry Commitment to Combating Coronavirus Print Ad
In these unprecedented times, America’s biopharmaceutical companies are coming together to achieve one shared goal: the eradication of COVID-19. The decades-long investments we made in new technology, research and treatments have prepared us to act swiftly.
Fighting Variants of COVID-19
As the world continues to feel the impact of the COVID-19 pandemic, the biopharmaceutical industry is working around the clock to develop and manufacture safe and effective vaccines. Across the industry, companies are further continuing clinical research to assess whether modifications or boosters are warranted to existing vaccines to address emerging variants.
